S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS. (23rd June 2022)

Record Type:: Journal Article
Title:: S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS. (23rd June 2022)
Main Title:: S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
Authors:: Garcia-Manero, G.
Winer, E. S.
DeAngelo, D. J.
Tarantolo, S.
Sallman, D. A.
Dugan, J.
Groepper, S.
Giagounidis, A.
Götze, K.
Metzeler, K. H.
Li, C.-C.
Zhou, L.
Martinez, E.
Lane, M.
von Roemeling, R.
Bohme, M.
Kubasch, A. S.
Verma, A.
Platzbecker, U.
Abstract:
Is Part Of:: HemaSphere. Volume 6(2022)Supplement 3
Journal:: HemaSphere
Issue:: Volume 6(2022)Supplement 3
Issue Display:: Volume 6, Issue 3 (2022)
Year:: 2022
Volume:: 6
Issue:: 3
Issue Sort Value:: 2022-0006-0003-0000
Page Start:: 30
Page End:: 31
Publication Date:: 2022-06-23
Subjects:: Hematology -- Periodicals
616.15005
Journal URLs:: https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:: 10.1097/01.HS9.0000843408.31385.3f ↗
Languages:: English
ISSNs:: 2572-9241
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 22682.xml